Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of PERINDOPRES® TRIO vs TRIPLIXAM®
NCT05470764Phase 1Completed
- Sponsor
- Darnitsa
- Start
- May 2021
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of perindopril + indapamide + amlodipine in hypertension (HTN), heart failure (HF) and coronary artery disease (CAD) (2 arms), sponsored by Darnitsa. Primary endpoints: Maximum Plasma Concentration of Perindopril at 36 hours, Area Under the Concentration-Time Curve of Perindopril at 36 hours and 4 more. Started May 2021; status: completed.
02
Drugs
perindopril + indapamide + amlodipine
03
Conditions
hypertension (HTN)heart failure (HF)coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT05470764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05470764.